Literature DB >> 20199544

Identification of a primarily neurological phenotypic expression of xeroderma pigmentosum complementation group A in a Tunisian family.

O Messaoud1, M Ben Rekaya, R Kefi, S Chebel, A Boughammoura-Bouatay, H Bel Hadj Ali, N Gouider-Khouja, J Zili, M Frih-Ayed, I Mokhtar, S Abdelhak, M Zghal.   

Abstract

Xeroderma pigmentosum (XP) is a rare genodermatosis predisposing to skin cancers. The disease is classified into eight groups. Among them, XP group A (XP-A) is characterized by the presence of neurological abnormalities in addition to cutaneous symptoms. In the present study, we report a particular family with XP-A in which some members showed an atypical clinical presentation, i.e. unexplained neurological abnormalities with discrete skin manifestations. Molecular investigation allowed identification of a novel XPA mutation and complete phenotype-genotype correlation for this new phenotypic expression of XP-A.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20199544     DOI: 10.1111/j.1365-2133.2010.09646.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  3 in total

1.  A novel POLH gene mutation in a xeroderma pigmentosum-V Tunisian patient: phenotype-genotype correlation.

Authors:  Mariem Ben Rekaya; Olfa Messaoud; Amel Mebazaa; Olfa Riahi; Hela Azaiez; Rim Kefi; Mohamed Zghal; Samir Boubaker; Ahlem Amouri; Amel Ben Osman-Dhahri; Sonia Abdelhak; Mourad Mokni
Journal:  J Genet       Date:  2011-12       Impact factor: 1.166

Review 2.  Therapeutics of xeroderma pigmentosum: A PRISMA-compliant systematic review.

Authors:  Fernando Antônio Gomes de Andrade; Claudio Eduardo de Oliveira Cavalcanti; Felipe Contoli Isoldi; Lydia Masako Ferreira
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Mar-Apr       Impact factor: 2.545

3.  Genetics and genomic medicine in Tunisia.

Authors:  Houda Elloumi-Zghal; Habiba Chaabouni Bouhamed
Journal:  Mol Genet Genomic Med       Date:  2018-03       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.